EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio

Clearmind Medicine Inc CMND has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of its overarching strategy to strengthen its IP portfolio further.

What Happened: The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia and expands Clearmind's portfolio for innovative molecules, new indications, and treatments. 

Dyskinesia is a category of movement disorders characterized by abnormal involuntary movements. It may manifest as chorea (irregular, involuntary movements of the body, especially the face, and extremities) or dystonia (disorder or lack of muscle tonicity). 

Why It Matters: In addition, the patent application includes protection for its unique combination of 3-MMC and SciSparc's Palmitoylethanolamide for Dyskinesia as part of its ongoing collaboration with SciSparc Ltd SPRC.

Clearmind has a broad IP footprint in the psychedelic space, with 30 patents and patent applications across 14 patent families.

The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

Price Action: CMND shares closed at $0.42 on Monday.